| Literature DB >> 35741934 |
Lucia Ferron1,2, Chiara Milanese3, Raffaella Colombo1, Raffaele Pugliese4, Adele Papetti1.
Abstract
A polysaccharide fraction obtained from camelina cake (CCP), selected as a carrier to encapsulate purple corn cob extract (MCE), was investigated. A wide population of carbohydrate polymers (with a polydispersivity index of 3.26 ± 0.07 and an average molecular weight of about 139.749 × 103 ± 4.392 × 103 g/mol) with a gel-like behavior and a thixotropic feature characterized the fraction. MCE-CCP combinations (50-50 and 25-75, w/w), selected based on CCP encapsulation efficiency, were tested for their stability and MCE polyphenols' bioaccessibility during digestion (monitored using an in vitro static procedure). During the oral and gastric phases of the digestion process, CCP gradually swelled and totally released MCE polyphenols. MCE-CCP50 had the fastest release. Moreover, anthocyanins were still detectable during the duodenal phase, in both MCE-CCP ingredients. Furthermore, CCP (5 mg/mL) exerted in vitro potential hypocholesterolemic activity via bile salts binding during digestion.Entities:
Keywords: anthocyanin bioaccessibility; by-product; camelina cake polysaccharide; carrier; purple corn cob; stabilizer
Year: 2022 PMID: 35741934 PMCID: PMC9223137 DOI: 10.3390/foods11121736
Source DB: PubMed Journal: Foods ISSN: 2304-8158
Figure 1Rheological studies on the viscoelastic properties of CCP. (a) Viscosity measurements for increasing the shear rate of CCP. (b) Frequency-dependent oscillatory rheology (0.1–100 Hz) of CCP featuring a predominant solid-elastic behavior (G’) as compared to the viscous component (G”), (c) Average values of storage (G’—blue color) and loss (G”—red color) moduli obtained from frequency-sweep tests. (d) Thixotropy test of CCP solution showing its space-filling propensity.
Bioaccessibility index registered for each selected Moradyn Cob Extract (MCE) polyphenol during in vitro digestion of MCE-CCP50.
| Bioaccessibility Index (%) | |||||||
|---|---|---|---|---|---|---|---|
| Compound | Oral Phase | Gastric Phase | Gastric Phase | Gastric Phase | Gastric Phase (2 h) | Duodenal Phase | Duodenal Phase |
| Expected | 50 | 25 | 25 | 25 | 25 | 12.5 | 12.5 |
| Cyanidin-3- | 35.36 ± 0.06 | 22.18 ± 1.81 | 22.33 ± 2.59 | 20.59 ± 1.56 | 23.12 ± 0.48 | 4.58 ± 1.25 | 2.72 ± 0.01 |
| Perlagonidin-3- | 39.26 ± 2.11 | 24.35 ± 1.37 | 23.49 ± 2.54 | 22.53 ± 1.63 | 24.12 ± 0.78 | 6.08 ± 0.62 | 5.18 ± 0.03 |
| Peonidin-3- | 48.96 ± 0.48 | 26.94 ± 1.41 | 27.45 ± 3.18 | 26.31 ± 2.26 | 28.04 ± 0.67 | 5.53 ± 1.69 | 2.60 ± 0.26 |
| Ferulic acid derivative | 44.87 ± 1.95 | 21.36 ± 0.13 | 22.48 ± 1.79 | 25.38 ± 2.12 | 23.41 ± 2.29 | n.d. | n.d. |
| Myricetin-7- | 33.25 ± 2.85 | 21.05 ± 0.23 | 24.55 ± 0.64 | 23.28 ± 0.28 | 24.46 ± 3.94 | 12.14 ± 1.13 | n.d. |
| Isorhamnetin-3,7-di- | 41.82 ± 2.84 | 23.29 ± 0.01 | 23.37 ± 0.07 | 26.78 ± 1.25 | 24.22 ± 3.34 | 11.45 ± 1.99 | 3.66 ± 1.04 |
| Quercetin-7- | 93.07 ± 1.95 | 70.28 ± 7.67 | 79.11 ± 0.91 | 90.27 ± 3.62 | 91.34 ± 10.61 | 33.49 ± 7.23 | 35.42 ± 4.88 |
| Quercetin-7- | 64.09 ± 0.66 | 36.02 ± 2.17 | 35.97 ± 1.12 | 39.46 ± 4.00 | 35.88 ± 1.15 | 13.80 ± 2.96 | 10.30 ± 1.86 |
| Kaempferol-7- | 62.69 ± 0.69 | 32.02 ± 3.80 | 34.40 ± 1.56 | 33.68 ± 1.56 | 33.74 ± 0.40 | 12.96 ± 3.55 | 10.48 ± 1.68 |
| Isorhamnetin-7- | 59.98 ± 0.46 | 30.23 ± 0.17 | 31.81 ± 0.05 | 51.04 ± 10.65 | 39.32 ± 6.49 | 13.11 ± 2.75 | 14.63 ± 1.87 |
| Isorhamnetin-3- | 57.57 ± 1.47 | 25.80 ± 0.82 | 27.55 ± 1.00 | 27.86 ± 3.70 | 27.36 ± 1.53 | 11.63 ± 3.02 | 11.64 ± 3.02 |
| Luteolin-7- | 66.52 ± 1.56 | 21.48 ± 0.54 | 23.24 ± 0.19 | 27.02 ± 0.47 | 25.86 ± 2.72 | 10.20 ± 2.69 | 11.83 ± 1.76 |
| Kaempferol-3- | 66.34 ± 1.85 | 36.71 ± 1.62 | 34.68 ± 0.74 | 35.85 ± 2.17 | 35.22 ± 2.57 | 20.18 ± 3.67 | 19.17 ± 3.45 |
Note: Following INFOGEST protocol, samples were diluted 1:1 (v/v) at the beginning of each digestion phase; thus, the expected bioaccessibility index was based on this dilution factor. n.d.: not determined.
Bioaccessibility index registered for each selected Moradyn Cob Extract (MCE) polyphenol during in vitro digestion of MCE-CCP75.
| Bioaccessibility Index (%) | |||||||
|---|---|---|---|---|---|---|---|
| Compound | Oral Phase | Gastric Phase | Gastric Phase | Gastric Phase | Gastric Phase (2 h) | Duodenal Phase | Duodenal Phase |
| Expected | 50 | 25 | 25 | 25 | 25 | 12.5 | 12.5 |
| Cyanidin-3- | 56.09 ± 1.77 | 30.28 ± 4.40 | 27.75 ± 4.34 | 24.83 ± 1.49 | 28.83 ± 0.96 | 5.35 ± 0.08 | 2.78 ± 0.07 |
| Perlagonidin-3- | 56.77 ± 0.13 | 32.11 ± 3.10 | 29.19 ± 3.86 | 26.83 ± 0.03 | 30.33 ± 2.10 | 6.34 ± 0.53 | 2.24 ± 0.19 |
| Peonidin-3- | 75.24 ± 0.07 | 38.32 ± 4.80 | 35.03 ± 5.10 | 31.98 ± 1.65 | 36.37 ± 1.82 | 6.59 ± 0.75 | n.d. |
| Ferulic acid derivative | 63.59 ± 0.32 | 32.02 ± 2.67 | 24.14 ± 4.41 | 18.12 ± 1.02 | 20.06 ± 0.01 | n.d. | n.d. |
| Myricetin-7- | 46.49 ± 1.89 | 30.51 ± 1.30 | 30.76 ± 1.46 | 23.83 ± 1.04 | 24.51 ± 0.18 | 13.06 ± 0.33 | 2.14 ± 0.82 |
| Isorhamnetin-3,7-di- | 63.54 ± 1.54 | 29.06 ± 1.34 | 30.94 ± 6.35 | 23.87 ± 1.92 | 25.05 ± 1.28 | 16.27 ± 3.38 | 3.51 ± 0.31 |
| Quercetin-7- | 89.89 ± 0.62 | 57.80 ± 4.00 | 60.58 ± 2.20 | 49.51 ± 0.29 | 53.40 ± 3.28 | 26.03 ± 5.83 | 23.50 ± 2.63 |
| Quercetin-7- | n.d. | 71.07 ± 2.74 | 66.77 ± 5.37 | 61.71 ± 0.43 | 67.24 ± 0.32 | 24.95 ± 1.86 | 7.06 ± 2.99 |
| Kaempferol-7- | 70.85 ± 1.43 | 39.86 ± 4.29 | 37.27 ± 8.36 | 30.89 ± 1.02 | 33.97 ± 1.40 | 13.27 ± 1.33 | 6.85 ± 1.72 |
| Isorhamnetin-7- | 67.80 ± 1.94 | 45.17 ± 5.16 | 35.40 ± 0.35 | 32.84 ± 0.61 | 44.30 ± 9.83 | 26.23 ± 4.00 | 20.00 ± 2.97 |
| Isorhamnetin-3- | 64.63 ± 1.32 | 30.41 ± 3.53 | 27.60 ± 4.89 | 23.92 ± 1.05 | 26.81 ± 1.15 | 12.22 ± 0.90 | 10.51 ± 0.28 |
| Luteolin-7- | 55.98 ± 1.82 | 26.90 ± 2.16 | 29.86 ± 10.74 | 20.93 ± 1.70 | 25.72 ± 2.94 | 12.45 ± 1.52 | 10.62 ± 0.64 |
| Kaempferol-3- | 81.84 ± 2.97 | 40.21 ± 3.39 | 31.82 ± 12.33 | 29.30 ± 2.68 | 33.13 ± 2.32 | 27.88 ± 2.57 | 24.96 ± 1.72 |
Note: Following the INFOGEST protocol, samples were diluted 1:1 (v/v) at the beginning of each digestion phase; thus, the expected bioaccessibility index was based on this dilution factor. n. d.: not determined.
Figure 2Experimental bioaccessibility index. Values registered for (a) cyanidin-3-O-glucoside, (b) perlagonidin-3-O-glucoside, and (c) peonidin-3-O-glucoside in MCE-CCP50 (light blue bars) and MCE-CCP75 (dark blue bars) at different time points. White bars represented the expected bioaccessibility index on a gradual dilution basis (occurring during the in vitro digestion process). Different lowercase letters indicate significant differences for each compound (p < 0.05).
Camelina Cake Polysaccharide (CCP) binding capacity (%) calculated for each primary bile salt (BS) or for the BS mixture (35% NaTC, 35% NaGC, 15% NaTCDC and 15% NaGCDC).
| Bile Acid Binding Activity (%) | |||||
|---|---|---|---|---|---|
| CCP (mg/mL) | NaTC | NaGC | NaTCDC | NaGCDC | BS Mixture |
| 0.50 | N.A. | N.A. | N.A. | N.A. | N.A. |
| 0.75 | N.A. | N.A. | N.A. | N.A. | N.A. |
| 2.50 | 38.21 ± 2.29 | 40.26 ± 2.25 | 41.27 ± 0.04 | 41.27 ± 2.13 | 39.88 ± 0.72 |
| 5.00 | 100.00 ± 0.13 | 100.00 ± 0.08 | 100.00 ± 0.01 | 100.00 ± 0.01 | 100.00 ± 2.97 |
| 10.00 | 100.00 ± 0.01 | 100.00 ± 0.07 | 100.00 ± 0.01 | 100.00 ± 0.01 | 100.00 ± 1.28 |
N.A. indicates no activity.
Figure 3Chromatographic profile of BS mixture in SIF tested at 10 mM final concentration, registered at 208 nm. (1) NaTC, (2) NaGC, (3) NaTCDC, (4) NaGCDC.